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ta.2012.1Abstract Background: Esthesioneuroblastoma (ENB), also known as olfactory neuroblastoma, is
a rare and aggressive malignant tumour of the nasal cavity and paranasal sinuses. This study was
conducted to evaluate and analyse the outcomes of the combined modality regimen including sur-
gery, radiotherapy and chemotherapy.
Methods: From January 2001 to January 2012; in a retrospective analysis; 10 patients with ENB
were treated in Mansoura University Hospitals at the Otolaryngology Department. Four patients
were of Kadish stage B and six were of stage C. In four cases of stage C, invasion of the anterior
cranial fossa was detected. No patient had lymph nodes or distant metastases. All patients received
a combined multimodality treatment including surgery; craniofacial or endoscopic resections;
radiotherapy and combined vepesid and cisplatin chemotherapy.
Results: Nine patients, over an average follow-up which ranged from 5 to 8 years (mean 6.2; SD
3.01), are actually alive with no evidence of disease in eight patients and locoregional recurrence in
one patient who underwent salvage therapy. However, the overall survival of the nine patients was1001908407; fax: +20 50
ail.com, ahmusaad@mans.
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Table 1 Stages of ENB, according
Stage Tumour localization
A Conﬁned to the nasal cavity
B Conﬁned to the nasal cavity
C Beyond the nasal cavity and
cavity
D With metastasis to cervical ly
18 E. Kamal et al.5.3–8.75 years (mean 6.4; SD 3.04). Local recurrence and distant metastasis were detected in one
patient with an average survival of 3 years.
Conclusions: ENB can be a highly curable sinonasal malignancy. Combined modality treatment
is considered an integral part of management protocol.
ª 2013 Egyptian Society of Ear, Nose, Throat and Allied Sciences.
Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Esthesioneuroblastoma (ENB), also known as olfactory neuro-
blastoma, is a rare and aggressivemalignant tumour of the nasal
cavity and paranasal sinuses. The tumour is thought to originate
from the specialized neuroepithelium of the upper nasal cavity.1,2
It stands for 6% of nasal cavity/paranasal sinuses cancers 3 and
0.3% of the upper aero-digestive tract malignancies.4
The Kadish Staging system, ﬁrst described in 1976 5, has
been the most commonly used and was modiﬁed by Morita
et al. (1993) 6 (Table 1), such that stages C and D are classiﬁed
as advanced stages. In advanced olfactory neuroblastoma, the
tumour is a locally aggressive neoplasm that frequently invades
the skull base and orbit.7–9 Craniofacial resection (CFR) com-
bined with radiotherapy and/or chemotherapy has resulted in
a signiﬁcantly improved survival rate. The 5 year survival rate
has improved from 37.5% to 82% with CFR treatment.7 How-
ever, notwithstanding aggressive therapy, locoregional recur-
rence and long-range metastasis frequently develop, late after
initial therapy.8 Locoregional recurrence is the most common
cause of treatment failure and salvage therapies play an impor-
tant role in the control of olfactory neuroblastoma.9
Because of the rarity of ENB, experience with this tumour
has been limited and no consensus has been reached in its man-
agement. However, the literature gives little support to single-
regimen treatments. Since then, different therapy protocols
have been applied including CFR, radiation therapy and che-
motherapy in different combinations aiming for optimizing the
outcome results of management.
The purpose of this study is to review the 10 years experi-
ence of the Otolaryngology Department in cooperation with
the Neurosurgery Department and the Clinical Oncology
and Nuclear Medicine Department, Mansoura University
Hospitals (MUH), in applying treatment modalities including
CFR, endoscopic resection, radiation therapy and chemother-
apy for ENB of different stages.
2. Materials and methods
After the approval of the local Research and Ethics Committee
of Mansoura University, we conducted a retrospective chart
review of patients with ENB who were treated at the Otolaryn-
gology Department of MUH from 2001 to 2012. A retrospec-
tive analysis based on medical records, operating reports,to Kadish and modiﬁed by Mo
and paranasal sinuses
paranasal sinuses, including involv
mph nodes or distant metastasisradiation therapy and chemotherapy records was performed
on 10 patients with biopsy proved ENB. Patients’ demograph-
ics, protocol of management, tumour recurrence, disease free
survival and complications were reviewed.
The diagnosis of ENB was based on histopathological fea-
tures, including microscopic ﬁndings of uniform small round
blue cells with scant cytoplasm and hyperchromatic nuclei with
inconspicuous nucleoli. Other features included neuroﬁbrils, ro-
settes, pseudorosettes and neurosecretory granules. Conﬁrma-
tion of the diagnosis was made through immunohistochemical
analysis for all patients, including staining for synaptophysin,
CD56, S-100 protein and neuron speciﬁc enolase (alone or in
combination with each other).
Before any surgical intervention, a nasal endoscopy and a re-
view of the patient’s radiology (CTandMRI)were performed to
evaluate the extent of the primary disease particularly regarding
the intracranial extension, tumour inﬁltration of the dura, deep
inﬁltration of the orbit or signiﬁcant involvement of pterygopal-
atine fossa. Preoperative preparation included nasal biopsy,
ultrasonography of the neck and abdomen, chest radiography
and bone scan, to exclude lymph node or distant metastases.
Disease staging was classiﬁed as A, B or C according to the
criteria established by Kadish et al. We preferred to use this
staging system to allow comparison with other series as it re-
mains the most commonly used in the literature.
The decision of the proper management protocol was made
for every patient individually after a group meeting including
the otolaryngologic oncology team, the neurosurgical team
and the nuclear medicine team. Explanations of treatment op-
tions were regularly offered to all patients and discussed with
them in order to clarify the advantages and side effects of
the different treatment regimens applied to them. An informed
consent form, signed by the patient or the patient’s guardian,
was always obtained before surgery.3. Results
From January 2001 to January 2012, 10 patients with ENBwere
identiﬁed and treated at theMUH.Nine patients were primarily
managed in our institute and one patient was referred to us with
a residual disease (stage B) after having a non-craniofacial sur-
gery outside the hospital and was immediately enrolled into our
protocol. Six patients were female and four were male. Theirrita.
ement of the cribriform plate, base of the skull, orbit or intracranial
Table 2 Management protocols and outcome of 10 patients with esthesioneuroblastoma.








1 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 8.75
2 B ER No V–P 6 cycles 60 Gy NED No 8.58
3 B ER No V–P 6 cycles 60 Gy NED Local/metastases 2
4 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 7.17
5 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 7.08
6 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 6.92
7 B ER No V–P 6 cycles 60 Gy NED Local 6.83
8 B CFR No V–P 6 cycles 60 Gy NED No 6.67
9 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 5.5
10 C CFR V–P 4 cycles V–P 2 cycles 60 Gy NED No 5.33
CFR, craniofacial resection; ER, endoscopic resection; V–P, chemotherapy with vepesid and cisplatin; NED, no evidence of disease.
Esthesioneuroblastoma: Mansoura University Hospitals’ 19ages at the time of diagnosis ranged from 14 to 37 years (mean
24.5; SD 8.96).
The presenting complaints were in the form of epistaxis (8/10), na-
sal obstruction (7/10), nasal discharge (5/10), headache (3/10) and
proptosis (2/10). Clinical, radiologic and pathologic data were used
for tumour staging. Four patients were of stage B and six were of
stage C. In four cases of stage C, invasion of the anterior cranial fossa
was detected but there was no invasion of the orbit or the brain in any
patient of this series. There were no hormone-related symptoms, cra-
nial nerves involvement, visual disturbance or evidence of lymph node
or distant metastases at presentation. Follow-up time was in the
range of 5 to 8 years (mean 6.2; SD 3.01).3.1. Surgery
Seven patients (sixwith stageC and onewith stageB) had under-
gone anterior craniofacial resection through a combined neuro-
surgical-otolaryngological approach and 3 patients with stage B
were managed by endoscopic resection. In CFR, after an ade-
quately sized craniotomy had been performed, the cribriform
plate and any invaded dura overlying the cribriform plate were
removed en blockwith tumour to achieve adequatemacroscopic
surgical margins. Reconstruction of the anterior skull base was
done in multiple layers using either local ﬂaps, autologous con-
nective tissue, or a synthetic heterologous dura substitute.
The endoscopic resection was performed on the 3 patients in a
piecemeal fashion. In this approach, endoscopic medial maxillec-
tomy, anterior and posterior ethmoidectomy, removal of lamina
papyracea and resection of the cribriform plate and the overlying
dura; when indicated; were done. Endoscopic duraplasty was per-
formed by using a synthetic heterologous dural substitute as an
underlay graft and autologous fascia lata overlay graft.
No patient underwent elective neck dissection as part of the
primary treatment and just one patient had salvage surgery in
the form of endoscopic cranial resection; plus adjuvant chemo-
therapy; 4 years after the initial treatment.
3.2. Chemotherapy
All the patients received combination chemotherapy in the
form of vepsid and cisplatin (V–P). This was done in a
regimen of four cycles as a neoadjuvent chemotherapy and
two postoperative cycles in 6 patients (stage C), and six post-
operative cycles in 4 patients (stage B).In V–P combination chemotherapy regimen, vepsid was
delivered in a dose of 100 mg/m2 on day 1 to day 3, and cis-
platin in a dose of 100 mg/m2 on day 1. Chemotherapy was re-
peated in cycles of 21 days. Responses were evaluated starting
from the 4th cycle.
Overall toxicities were mild and manageable in all patients
with symptomatic care and there was no indication in any pa-
tient to reduce the dose or to stop the chemotherapy.
3.3. Radiotherapy
Preoperative radiotherapy was not used in any one of the 10
patients. Postoperative radiotherapy to the primary site;
2 weeks after the end of chemotherapy; was part of the initial
treatment protocol in all patients and the neck was not treated
in any of our patients.
Radiotherapy was delivered to the patients using the linear
accelerator 6 mcv photon with CT localization of the ﬁeld and
dimension measuring according to the pretreatment measures
i.e. tumour localization and size at time of presentation. Radio-
therapy was planned with one anterior and two lateral wedge
pair ﬁelds with unequal weighing. All patients received a con-
ventionally fractionated irradiation (30 fractions), i.e. 2 Gy
per fraction ﬁve times a week, to a total of 60 Gy in 6 weeks.
3.4. Summary of the treatment regimens and outcomes of the 10
patients
Table 2 shows summary of the used treatment regimen in every
patient, outcomes and overall survival. After completion of
treatment regimen, there was no evidence of the disease in all
patients and that was evaluated clinically and radiologically
(Fig. 1). Follow-up MRI was done every 3 months in the ﬁrst
2 years, then every 6 months for the next 3 years. Local recur-
rence was detected in 2 patients, 1 female patient after
18 months and 1 male patient after 40 months. Both of them
were of stage B and underwent endoscopic resection. The fe-
male patient developed bone metastases and died 5 months la-
ter and the male patient had salvage therapy and is still alive
with no evidence of disease. No locoregional recurrence or dis-
tant metastases were detected in the rest of the patients (8/10
patients) in a follow-up period of about 8 years in 2 patients,
6.5 years in 2 patients, 6 years in 2 patients, and 5 years in 2
patients. The overall survival in the 9 patients ranged from
5.3 to 8.75 years (mean 6.4; SD 3.04). Although these results
Figure 1 MRI of 1 patient with Stage C ENB with intracranial extension. (a) Before chemotherapy, (b) After neoadjuvant four cycles of
V–P chemotherapy, (c) Six years after CFR and completing the regimen of chemo-radiotherapy.
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the outcomes needs a longer evaluation period with strict fol-
low-up records. However, 9 patients in this study are still alive
with no detectable evidence of ENB and with no report of any
medical problems.4. Discussion
ENB is a rare entity of malignancy that can be associated with
a very long survival and most reports were in small series sim-
ilar to the present study that evaluates the experience of a sin-
gle institution. Because of the paucity and heterogeneity of
published treatment regimens, there is no evidence-based con-
sensus of optimal management strategy.
However, pathological diagnosis of ENB is challenging as it
should be differentiated from other small blue cell neoplasms
and establishing a histopathological conﬁrmation is essential
before initiating treatments for ENB. Immunohistochemistry
is a valuable diagnostic tool using staining patterns for neu-ron-speciﬁc enolase, chromogranin, synaptophysin, S-100
and epithelial markers.10
ENB is initially demonstrated with a bimodal age distribu-
tion; it peaks ﬁrst between age 10 and 20 years and later be-
tween age 50 and 60 years, and is slightly more common in
females.11 The current study reports a mean age at diagnosis
of 24.5 years ± SD 8.96, which is consistent with the earlier
peak and 6 patients were female and 4 were male.
Given the absence of classic symptoms, and the similari-
ties between benign and malignant lesions at initial presenta-
tion may lead to a signiﬁcant delay in the diagnosis. Because
initial symptoms can be innocuous, 12.5% of patients will
present with intracranial extension.12 Regional and distant
metastases occur in 14–38% of patients, most commonly
to lymph nodes, lungs and bones.13 We did not ﬁnd a
signiﬁcant difference between the clinical ﬁndings most com-
monly reported in the literature and those described in our
study.
Several studies have compared the respective results of sur-
gery alone, radiotherapy alone, the combination of surgery
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Surgery followed by adjuvant radiotherapy appears to be supe-
rior to radiotherapy or surgery alone.9 Based on a series of 274
patients, Jethanamest et al. conﬁrmed that the mean survival
of patients treated by a combination of surgery and radiother-
apy was 216.8 months (range: 188–245) versus 208 months for
surgery alone and 92.8 months for radiotherapy alone
(P < 0.002 radiotherapy versus combined therapy).14 Similar
results were published by Foote et al. in 1993.16 Combined
modality therapy with surgery, radiotherapy and chemother-
apy in various combinations, is progressively evolving over
the last few years. Also, outcomes improved signiﬁcantly with
the advent of CFR in comparison with extracranial ap-
proaches; resulting in a better local control rate.7,17
CFR was the procedure most commonly applied in our
group of patients and accounted for 70% (7/10) of the cases.
No locoregional recurrence or systemic metastases were de-
tected in the 7 patients who underwent CFR in a follow-up
time of 5.33–8.75 years and all of them are still alive. There
was no indication for elective or therapeutic neck treatments
in those patients and none of the patients developed recur-
rences in their neck after completing their regimen therapy.
Several authors have reported the possibility of complete
endoscopic resection of tumours conﬁned to the nasal cavity
and paranasal sinuses. The place of endoscopic surgery in
the treatment of ENB was the subject of a meta-analysis based
on 361 patients operated between 1992 (date of the ﬁrst known
publications on endoscopic surgery) and 2008. The authors
found better survival rates (overall and disease-free survival)
after endoscopic surgery than after open surgery. However,
these results are inﬂuenced by the fact that open surgery is
mainly performed for Kadish stage C and D disease. The
authors concluded that endoscopic surgery is possible but must
be reserved to less advanced tumours. The number of studies
comparing these two types of surgeries for advanced tumours
is insufﬁcient at the present time.18
In our study, we have only had three cases who underwent
endoscopic resection and all of them continued a post-opera-
tive adjuvant radiotherapy and chemotherapy. Two cases
had local relapse; one within the ﬁrst 2 years and the other
one within the fourth year. The former case died after
5 months as a result of developing bone metastases and the lat-
ter case had underwent a successful salvage therapy. The third
case is still alive with a disease free follow-up period of
8.58 years. In spite of the small sample size, our results support
other studies in considering endoscopic resection as a success-
ful alternative modality to standard surgical approaches for
ENB in highly selected patients.
Mclean et al.19 recently reported a study where frequent
locoregional recurrence remained a signiﬁcant problem despite
using the combined modality therapy and advances in surgical
techniques and radiotherapy technology. There were 8 recur-
rences of 21 patients (38%), 6 of them had undergone CFR
and 2 had undergone endoscopic resection. All patients who
developed recurrences had been initially treated with surgery
and postoperative radiotherapy and four of them received at
least four cycles of carbo- or cisplatin plus etoposide adjuvant
chemotherapy. According to the available data in this study, it
seems that radiotherapy and chemotherapy were delivered at
outside facilities and the dose and regimen applied were not
optimum in all cases.All the patients in this study; whether stage B or C disease;
received an aggressive combined modality of surgery, radio-
therapy and chemotherapy. Six patients with Kadish stage C
neoplasms received neoadjuvant chemotherapy of four cycles
aiming for reducing tumour burden and postoperative two cy-
cles, with a total of six cycles with V–P protocol. On the other
hand, 4 patients with Kadish stage B neoplasms received a to-
tal of postoperative six cycles. Radiotherapy was delivered in
all patients postoperatively 2 weeks after the end of chemo-
therapy in a total dose of 60 Gy over 6 weeks. None of our pa-
tients received preoperative radiotherapy and preoperative
chemotherapy regimen was successful in the 6 patients with
stage C disease in decreasing the tumour burden before resec-
tion and increasing the chance of a sound macroscopic total
resection.
Polin et al.20 found that preoperative radiation and chemo-
therapy can result in a reduced tumour burden, which in-
creases the chances of macroscopic total resection and long-
term disease-free progression. However, when radiotherapy is
given preoperatively, determination of tumour margins and
tissue planes can be complicated and result in an increased risk
of incomplete resection.
Chemotherapy has been used in the treatment of ENB with
mixed results. To date, the generally accepted role of chemo-
therapy has remained somewhat restricted to recurrent and
metastatic disease. When chemotherapy is used, combination
regimens have been the standard as chemotherapy appears
not to be curative as a single modality therapy. Results suggest
enhanced chemosensitivity with combination approaches.
Multiple agents have been used, including DTIC, actinomycin,
MTX, BCNU, procarbazine, platinum regimens, etoposide,
cyclophosphamide, vincristine and doxorubicin. Platinum-
based regimens have been most common.21
The University of Virginia has published a study of 34 pa-
tients treated since 1976. Eighty percent of patients underwent
CFR, 91% received preoperative radiation therapy, with most
receiving 5000 cGy. Preoperative chemotherapy was adminis-
tered to 47% of patients, in the sitting of stage C disease
and included cyclophosphamide and vincristine with or with-
out doxorubicin. Overall survival was 81% and 54% at 5
and 10 years, respectively. Disease-free survival at 5 years
was 86% for stage A and B and 60% for stage C. The Univer-
sity of Virginia treatment protocol includes preoperative radi-
ation therapy for all stages and preoperative combination
chemotherapy for stage C patients, followed by CFR surgical
excision.10,20
Based on a cohort of 311 patients, Jethanamest et al.
showed that 10 year overall survival and disease-free survival
(Kaplan–Meier analysis) were 83.4% and 90%, respectively,
for patients with a tumour con-ﬁned to the nasal cavity (mod-
iﬁed Kadish Type A), 49% and 68.3% for patients with a tu-
mour involving the paranasal sinuses (modiﬁed Kadish Type
B), 36% and 66.7% for patients with a tumour extending be-
yond the paranasal sinuses (modiﬁed Kadish Type C) and
13.3% and 35.6% for patients with metastatic disease (modi-
ﬁed Kadish Type D) (P < 0.01). Log-rank test comparisons
found Kadish stage (P< 0.01), treatment modality
(P< 0.002), lymph node status (P< 0.01), age at diagnosis
(P< 0.001) to be signiﬁcant predictors of survival.14,16
An aggressive multimodality protocol was used in this study
with an outstanding outcome. Ninety percent (9/10) of the pa-
22 E. Kamal et al.tients of this study are still alive with no locoregional relapse or
systemicmetastases in 8 patients in a follow-up time of 5–8 years
and local recurrence in one patient who received salvage ther-
apy. CFR is still considered the surgical approach of choice in
patients with ENB especially those with advanced disease.
Endoscopic resection should be seriously considered as an alter-
native choice in well selected patients. Neoadjuvant chemother-
apy in Kadish stage C disease is an efﬁcient tool in reducing
tumour burden before surgical resection. It was successful in
decreasing the risk of incomplete resection associated with pre-
operative radiotherapy in other series as a result of difﬁculty of
determining tumour margins and tissue planes. The strict time
schedule and proper dosing in applying the multimodality regi-
men are critical in patients with ENB and any disturbance of the
determined protocol has a great impact on the outcome. A team
including the otolaryngologic surgeons, neurosurgeons and nu-
clearmedicine oncologists is instrumental in outlining and deliv-
ering treatment. In spite of the short follow-up period in this
study, the results of this series are highly encouraging in using
such an applied multidisciplinary approach. However, an ex-
tended follow-up time is always required for deﬁnitive evalua-
tion of regimen outcomes in cases with ENB.
5. Conclusions
ENB can be a highly curable sinonasal malignancy even in pa-
tients presenting with advanced diseases. Combined modality
regimen is considered an integral part of management proto-
col. CFR remains the optimum surgical option in advanced
diseases and endonasal endoscopic resection can be deeply
considered in carefully selected cases. Neoadjuvant chemother-
apy using V–P protocol without radiotherapy is successful in
reducing tumour burden.
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